TiGenix: Publication of prospectus and response memorandum for Takeda takeover bid commencing on April 30, 2018

    NEXT STORY
    ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)
    PREV STORY
    CrownBio Melancarkan Model Sasaran Disesuaikan Baharu untuk Imunoterapi
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

    author_avatar
    NASDAQ Market News

    Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    author_avatar
    NASDAQ Market News

    Wellington Partners raises EUR 210 million life science fund

    author_avatar
    NASDAQ Market News